rivastigmine clinical trials
Jump to navigation
Jump to search
Introduction
Reviewer's conclusions[1]:
- rivastigmine appears to be beneficial for people with mild to moderate Alzheimer's disease
- in comparison to placebo, 6-12 mg QD improved
- cognitive function
- activities of daily living (ADL)
- severity of dementia
- adverse effects consistent with cholinergic agonist activity
- economic impact not investigated
Methods
- 7 controlled trials involving 3370 individuals included
- 2.1 point improvement in cognitive function on ADAS-Cog score relative to placebo
- 2.2 point improvement in ADL determined by progressive deterioration scale
Additional terms
- activities of daily living (ADL)
- Alzheimer's disease assessment scale (ADAS)
- cognition (intelligence)
- rivastigmine (Exelon)
References
- ↑ Jump up to: 1.0 1.1 Birks et al, Rivastigmine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library, 2, 2001
- ↑ Schneider et al, Int J Geriatri Psychpharmacology, 1:S26-S34, 1998